CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 132 enrolled
Drug / intervention
ABT-981 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02384538
NCT02384538Phase 2Completed
CompareCT.gov

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-981 to Placebo in Subjects With Erosive Hand Osteoarthritis

AbbVie·interventional·Posted Mar 10, 2015·Updated Aug 11, 2017

In Brief

A Phase 2 clinical trial evaluating ABT-981 and Placebo for ABT-981 for Erosive Hand Osteoarthritis. Completed, enrolled 132 participants.

Detailed Summary

This is a multicenter, randomized, double-blind, placebo-controlled study to compare the safety and efficacy of ABT-981 to placebo in subjects with erosive hand osteoarthritis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsErosive Hand Osteoarthritis
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 10, 2015
Enrollment StartMar 1, 2015
Primary CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.3 years ago

Interventions

ABT-981biological

ABT-981 administered by subcutaneous injection

Placebo for ABT-981biological

Placebo for ABT-981 administered by subcutaneous injection